HALP and SII: Innovative Biomarkers for Diagnosing Ovarian Cancer in Both Epithelial and Non-Epithelial Subtypes

Steven Ridwan; Kemala Isnainiasih Mantilidewi; Gatot Nyarumenteng A.W.; Andi Kurniadi; Dodi Suardi; Siti Salima; Syahrul Rauf; Yudi Mulyana Hidayat

doi:10.24198/obgynia.v8i2.882

HALP and SII: Innovative Biomarkers for Diagnosing Ovarian Cancer in Both Epithelial and Non-Epithelial Subtypes

Steven Ridwan, Kemala Isnainiasih Mantilidewi, Gatot Nyarumenteng A.W., Andi Kurniadi, Dodi Suardi, Siti Salima, Syahrul Rauf, Yudi Mulyana Hidayat

Abstract

Objective: To evaluate the diagnostic utility of PHAL (Platelet, Hemoglobin, Albumin, and Lymphocyte), SII (Systemic Immune Inflammation Index), and SIRI (Systemic Inflammatory Response Index) for both epithelial and non-epithelial ovarian cancer.
Methods: A cross-sectional study of 156 patients with ovarian masses was conducted using preoperative laboratory data to calculate PHAL, SII, and SIRI scores. Histopathology confirmed diagnoses. Population I included all ovarian cancer types and benign tumors, while Population II included only non-epithelial ovarian cancer and benign tumors. Statistical analysis using SPSS 25.0, involved ROC curve and validity testing to assess diagnostic performance.
Result: SII showed the best performance in the overall population (AUC 0.738; sensitivity 71.25%; specificity 72.37%; accuracy 71.79%; LR+ 2.58; LR– 0.40). In the subgroup of non-epithelial ovarian cancer versus benign tumors, PHAL had the highest diagnostic accuracy (AUC 0.819; sensitivity 81.81%; specificity 73.68%; accuracy 75.51%; LR+ 3.11; LR– 0.25).
Conclusion: PHAL and SII are effective, accessible, and low-cost biomarkers that can support ovarian cancer diagnosis through routine blood tests.

PHAL dan SII: Biomarker Inovatif untuk Diagnosis Kanker Ovarium Subtipe Epitel dan Non-Epitel

Abstrak
Tujuan: Penelitian ini bertujuan untuk mengevaluasi nilai diagnostik dari PHAL (Platelet, Haemoglobin, Albumin, dan Limfosit), SII (Systemic Immune Inflammation Index), dan SIRI (Systemic Inflammatory Response Index) pada kanker ovarium epitelial dan non-epitelial.
Metode: Penelitian dengan metode potong lintang ini melibatkan 156 pasien dengan massa ovarium. Data laboratorium pra-operatif digunakan untuk menghitung skor PHAL, SII, dan SIRI. Diagnosis ditegakkan melalui pemeriksaan histopatologi. Populasi I mencakup semua jenis kanker ovarium dan tumor jinak, sedangkan Populasi II hanya mencakup kanker ovarium non-epitelial dan tumor jinak. Analisis statistik dilakukan menggunakan SPSS 25.0, termasuk analisis kurva ROC dan uji validitas untuk menilai kinerja diagnostik.
Hasil: Hasil penelitian menyimpulkan bahwa SII memiliki performa terbaik pada seluruh populasi (AUC 0,738; sensitivitas 71,25%; spesifisitas 72,37%; akurasi 71,79%; LR+ 2,58; LR– 0,40). Pada subkelompok kanker ovarium non-epitelial dibandingkan dengan tumor jinak, PHAL menunjukkan akurasi diagnostik tertinggi (AUC 0,819; sensitivitas 81,81%; spesifisitas 73,68%; akurasi 75,51%; LR+ 3,11; LR– 0,25).
Kesimpulan: PHAL dan SII merupakan biomarker yang efektif, mudah diakses, dan berbiaya rendah yang dapat mendukung diagnosis kanker ovarium melalui pemeriksaan darah rutin. Kata kunci: Kanker ovarium, Skor PHAL (Platelet-Hemoglobin-Albumin-Limfosit), Systemic Immune-Inflammation Index, Systemic Inflammatory Response Index

Keywords

Haemoglobin-albumin-lymphocyte- platelet (HALP) score, Ovarian cancer, Systemic Immune-Inflammation Index, Systemic Inflammatory Response Index

Full Text:

PDF

References

Ovarian Cancer Research Alliance. Ovarian Cancer Statistics [Internet]. 2015. Available from: https://ocrahope.org/for-patients/gynecologic-cancers/ovarian-cancer/ovarian-cancer-statistics/

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.

YAE P. Peran serum angiotensin-2, palmitat, trombositosis, rasio netrofil limfosit, rasio trombosit dan RMI2 sebagai prediktor tumor ganas ovarium. Univ Padjajaran.

Feharsal Y, Putra AD. International Ovarian Tumor Analysis (IOTA) Scoring System to Predict Ovarian Malignancy Preoperatively. Indones J Obstet Gynecol. 2016;42–6.

Winarto H, Laihad BJ, Nuranna L. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2014;15(5):1949–53.

Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet Off organ Int Fed Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61–85.

Esophagus Cancer Early Detection , Diagnosis , and Staging Can Esophageal Cancer Be Found Early ? [Internet]. Am Cancer Soc. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8661.00.pdf

Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? Int J Environ Res Public Health. 2022 Jan;19(3).

Chen XL, Xue L, Wang W, Chen HN, Zhang WH, Liu K, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015 Dec;6(38):41370–82.

Leetanaporn K, Hanprasertpong J. Predictive Value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index on the Oncological Outcomes of Locally Advanced Cervical Cancer Patients. Cancer Manag Res. 2022;14:1961–72.

Guo Y, Shi D, Zhang J, Mao S, Wang L, Zhang W, et al. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy. J Cancer. 2019;10(1):81–91.

Njoku K, Barr CE, Ramchander NC, Crosbie EJ. Impact of pre-treatment prognostic nutritional index and the haemoglobin, albumin, lymphocyte and platelet (HALP) score on endometrial cancer survival: A prospective database analysis. PLoS One. 2022;17(8):e0272232.

Farag CM, Antar R, Akosman S, Ng M, Whalen MJ. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types. Oncotarget. 2023 Feb;14:153–72.

Ertan K, Kara B, Disci SI, Vatansev H, Koksal Y. The Importance of Systemic Inflammatory Response Index, Systemic Immune-Inflammation Index, and Hemoglobin-Albumin-Lymphocytes-Platelets (HALP) Score in Children with Cancer. Iran J Pediatr. 2021;31(6).

Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front Physiol. 2018;9:1294.

Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000 Oct;85(4):599–610.

Zhang H, Lu J, Lu Y, Zhou J, Wang Z, Liu H, et al. Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma. PLoS One. 2017;12(5):e0177520.

Wang L, Qin X, Zhang Y, Xue S, Song X. The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis. Front Oncol. 2023;13:1006233.

Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021 Aug;36(8):841–8.

Feng J, Wang Q. Correlation of systemic immune-inflammatory response index with clinical data in patients with malignant ovarian tumor. Am J Transl Res. 2023;15(5):3309–17.

Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE, et al. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2019 Jan;33(1):e22624.

Zheng H, Tie Y, Wang X, Yang Y, Wei X, Zhao X. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses. Medicine (Baltimore). 2019 Feb;98(7):e14577.

Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020 Dec;12(12).

Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Commun Med. 2021;1.

DOI: http://dx.doi.org/10.24198/obgynia.v8i2.882